Tryptamine TherapeuticsASX: TYP

Actual: Jun 1, 2024

TRP-8803 Phase 1b trial commenced at CMAX Clinical Research, Adelaide; safety review confirmed safe and well-tolerated

Why it matters: IV psilocin delivery allows precise dose titration and rapid onset — advantages over oral psilocybin where absorption varies. Clean Phase 1b safety provides the foundation for the Phase 2 BED trial.

Actual: Jun 24, 2025

Swinburne University HREC approval for TRP-8803 BED Phase 2 trial

Why it matters: Ethics approval enables dosing in BED patients — a condition with very limited treatment options and high comorbidity with depression and anxiety.

Actual: Nov 1, 2025

Company renamed from Tryptamine Therapeutics to Entropy Neurodynamics (ASX ticker: TYP → ENP)

Why it matters: Rebrand reflects the company's broader neurodynamics platform beyond tryptamines alone. Signals maturation from early-stage psychedelic biotech to a clinical-stage neuroscience company.

Actual: Nov 21, 2025

TRP-8803 Phase 1b obesity PK sub-study completed — 3 participants dosed at CMAX Adelaide

Why it matters: PK data in obese patients is critical for eating disorder applications where patients may have altered drug distribution. Confirms IV psilocin achieves therapeutic exposure in this population.

Actual: Dec 1, 2025

First patient dosed in TRP-8803 BED Phase 2 at Swinburne University — world-first IV psilocin for a neuropsychiatric condition

Why it matters: Historic milestone: first IV psilocin administered to a psychiatric patient in a clinical trial. Trial design: 12 patients across 2 cohorts, 2 doses 14 days apart + psychotherapy. Cohort 1 = mid-range dose (140 min infusion), Cohort 2 = higher dose (60 min infusion).

Actual: Mar 1, 2026

Cohort 1 enrollment completed (6 of 6 patients); 2 patients completed both dosing sessions

Why it matters: First treated BED patient showed improvements at 4 weeks: reduced binge eating severity, depression, anxiety; gains in body image satisfaction. Topline Cohort 1 results expected Q1 2026.

Watch next: Cohort 1 topline data; Cohort 2 enrollment at higher dose

Actual: Jun 1, 2024

TRP-8802 Phase 2a fibromyalgia trial: 100% patient response rate (5 patients, 2 doses over 2 weeks)

Why it matters: Perfect response rate in a notoriously difficult-to-treat chronic pain condition. Small sample but signal is striking — fibromyalgia has limited effective treatments and high patient burden.

Actual: Jan 1, 2025

TRP-8802 Phase 2a IBS trial at MGH — interim data: 75% clinically meaningful reduction in abdominal pain (4 of 10 patients analyzed)

Why it matters: First FDA IND-approved psilocybin trial for IBS (NCT06206265). Interim data showing 75% pain reduction in a gut-brain disorder supports the neuroplasticity hypothesis for functional GI conditions.

Watch next: Full IBS trial results (completion expected H1 2025)